StocksRunner logo
mail
search
 
menu
 
Pfizer
$23.49
+0.17%
 
  Create Alerts  
  
  Overview  
  
  Analysis  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
 
 

PFE

 

Pfizer

$23.49

 
+$0.04 | +0.17%
 
  Create Alerts  
  
  Overview  
  
  Analysis  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
52W High
$ 31.54
 
 
MKT CAP
$ 133.55B
 
52W Low
$ 20.92
 
 
VOL
$ 47.28M
 
P/E Ratio
17.01
 
 
AVG VOL
$ 46.52M
 
RSI
52.71
 
 
TREND
Sideways
 
 
 

Chart

 
 

$22.04   (+6.58%)

$26.73   (-12.12%)

$26.44   (-11.16%)

$27.53   (-14.67%)

 
 
1year
6month
3month
1month
 
PFE Latest Headlines +
 
 
 
StocksRunner

Explore our PFE Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored PFE Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our PFE Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
StocksRunner
 
 
StocksRunner
Overview
 
StocksRunner
Trending
 
StocksRunner
Screener
 
StocksRunner
Ideas
 
StocksRunner
Top Rated
 
StocksRunner
Momentum
 
StocksRunner
Earnings
 
 

PFE

 

Pfizer

 

Current Price

 

$23.49

 
+$0.04 | +0.17%
 
 
52W High
$ 31.54
 
 
MKT CAP
$ 133.55B
 
52W Low
$ 20.92
 
 
VOL
$ 47.28M
 
P/E Ratio
17.01
 
 
AVG VOL
$ 46.52M
 
RSI
52.71
 
 
TREND
Sideways
 
 
 
  Create Alerts  
  
  Overview  
  
  Analysis  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
 
 
 
 
 
 

PFE Stock Analysis for the Last 90 Days

 
lock  Login to view Pfizer (PFE) recommendation from the last 90 days from financial news and social media.
 

Chart

 
 

$22.04   (+6.58%)

$26.73   (-12.12%)

$26.44   (-11.16%)

$27.53   (-14.67%)

 
 
1year
6month
3month
1month
 
 
 
 
 

PFE Latest Headlines

 
 
 

Pfizer succeeds in late-stage trial for colorectal cancer therapy.

 

Today

$23.49 | +0.17%
 
Activity

Pfizers Mega Deal Highlights Chinas Rising Role In Global Pharma.

 

Thu May 29, 2025

$23.45 | +1.19%
 
Activity
Potential

Pfizers Mega Deal Highlights Chinas Rising Role In Global Pharma.

 

Thu May 29, 2025

$23.45 | +1.19%
 
Activity
Potential

Pfizers Mega Deal Highlights Chinas Rising Role In Global Pharma.

 

Thu May 29, 2025

$23.45 | +1.19%
 
Activity
Potential

Pfizers Mega Deal Highlights Chinas Rising Role In Global Pharma.

 

Thu May 29, 2025

$23.45 | +1.19%
 
Activity
Potential

Pfizers Mega Deal Highlights Chinas Rising Role In Global Pharma.

 

Thu May 29, 2025

$23.45 | +1.19%
 
Activity
Potential

Pfizers Mega Deal Highlights Chinas Rising Role In Global Pharma.

 

Thu May 29, 2025

$23.45 | +1.19%
 
Activity
Potential

Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15 Companies and 20 Therapies | DelveInsight. Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15 Companies and 20 Therapies |. DelveInsightThe liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies including immunotherapies and targeted treatments. Increased R&.D investment. Emerging markets are also contributing throug

 

Tue May 27, 2025

$23.61 | +1.18%
 
Activity
Activity

Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15 Companies and 20 Therapies | DelveInsight. Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15 Companies and 20 Therapies |. DelveInsightThe liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies including immunotherapies and targeted treatments. Increased R&.D investment. Emerging markets are also contributing throug

 

Tue May 27, 2025

$23.61 | +1.18%
 
Activity
Activity

Pharma Stock Roundup: NVO CEO Resigns SNY to Buy VIGL & More. NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

 

Fri May 23, 2025

$23.32 | +1.35%
 
Activity
 
 
 
 
 
StocksRunner

Discover PFE Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of PFE. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our PFE Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

PFE Stock trends

PFE Stock performance

PFE Stock analysis

PFE investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 

UnAlert PFE Runner Alarm

Real-time signals powered by data
×

Price-Based

Triggers when the stock breaks through a known resistance level
 
Triggers when the stock drops below a key support level
 
Notifies if the stock moves up/down by a set percentage (e.g. ±5%)
 
Alerts when the stock hits a new high or low
 
Signals proximity to long-term highs or lows (e.g. within 5%)
 

Technical Indicator (Pro Plan)

Volume spikes 2x–3x above average. Indicates strong buying/selling pressure
 
Tracks large intraday swings, signaling potential opportunities or risk
 
Signals potential trend reversals or continuations
 
Long-term bullish/bearish trend signals from MA crossovers
 
RSI above 70 or below 30 to identify possible reversals
 
Signals momentum shifts
 

Fundamental (Master Plan)

Upcoming or just-released earnings reports
 
Alerts after results compared to expectations
 
Changes in rating or target price
 
New or changed dividends
 
Large trades by company insiders
 
M&A, lawsuits, product launches, etc
 
High volume/open interest in call/put contracts
 
Surge in mentions or sentiment shifts
 
 
 
Post ×
 
0/666
joker
 
 
 
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing PFE

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

 
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing PFE

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.